Investors who bought into VTVT at the lows have been lucky to float on a greasy orange smoke of financial wizardry by a company with a tiny float of their shares.
Alz drug laid off by Pfizer soon two decades ago. Bought by TransTech, later becoming VTVT who have now spent about 12 years to flop a P3 trial on both primary endpoints.
Who believes their CTAD post hoc subgroup data mining will convince anyone?- but hey their shares may well raise further and $AVXL decline on encouraging data.
News 
Market Data 
Discover 
